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Numerous studies of HIV-1 infection in hu-
mans and simian immunodefi  ciency  virus 
(SIV) infection in macaques have demon-
strated a correlation between CD8+ T cell re-
sponses and the restriction of viral replication. 
There is a temporal relationship between the 
development of CD8+ T cell responses and 
the decline in viremia after acute HIV-1 infec-
tion (1, 2). In addition, CD8+ T cell depletion 
in SIV-infected macaques leads to higher viral 
loads and faster disease progression (3–5). De-
spite immune pressure from CTLs, most HIV-
infected individuals experience high levels of 
ongoing viral replication. CTL escape muta-
tions commonly develop during infection with 
HIV-1 (6–12) and SIV (13–17). In some cases, 
these escape mutations have correlated directly 
with loss of viral suppression (18–20). There is 
also a correlation at a population level between 
mutations at specifi  c HIV-1 epitopes and the 
expression of MHC class I alleles capable of 
presenting those epitopes (21, 22). Collec-
tively, these studies suggest that CTL escape is 
an important mechanism of immune evasion, 
allowing ongoing viral replication and pro-
gressive loss of CD4+ T cells in most HIV-1–
infected individuals.
Some HIV-1–infected individuals, termed 
long-term nonprogressors (LTNPs), maintain 
high CD4+ T cell counts for many years with-
out antiretroviral treatment (23–25). A subset 
of LTNP, termed elite suppressors (ES), main-
tains viral loads of <50 copies of HIV RNA/
ml of plasma and normal CD4+ T cell counts 
without therapy. A large proportion of ES ex-
press the MHC class I allele HLA-B*57 (26). 
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Rare human immunodefi  ciency virus 1–infected individuals, termed elite suppressors (ES), 
maintain plasma virus levels of <50 copies/ml and normal CD4 counts without therapy. 
The major histocompatibility complex class I allele group human histocompatibility leuko-
cyte antigen (HLA)-B*57 is overrepresented in this population. Mutations in HLA-B*57–
restricted epitopes have been observed in ES, but their signifi  cance has remained unclear. 
Here we investigate the extent and impact of cytotoxic T lymphocyte (CTL) escape muta-
tions in HLA-B*57+ ES. We provide the fi  rst direct evidence that most ES experience 
chronic low level viremia. Sequencing revealed a striking discordance between the geno-
types of plasma virus and archived provirus in resting CD4+ T cells. Mutations in HLA-
B*57–restricted Gag epitopes were present in all viruses from plasma but were rare in 
proviruses, suggesting powerful selective pressure acting at these epitopes. Surprisingly, 
strong CD8+ T cell interferon-𝗄 responses were detected against some mutant epitopes 
found in plasma virus, suggesting the development of de novo responses to viral variants. 
In some individuals, relative CD8+ T cell interleukin-2 responses showed better correlation 
with the selection observed in vivo. Thus, analysis of low level viremia reveals an unexpect-
edly high level of CTL escape mutations refl  ecting selective pressure acting at HLA-B*57–
restricted epitopes in ES. Continued viral suppression probably refl  ects CTL responses 
against unmutated epitopes and residual or de novo responses against epitopes with 
escape mutations.
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One interesting study showed that some HLA-B*57+ ES 
have evidence of mutations in HLA-B*57–restricted epi-
topes in PBMC provirus, whereas others do not (27). The 
signifi  cance of these mutations has remained unclear. Because 
gag genes could not be amplifi  ed from plasma virus of ES 
with viral loads <50 copies/ml of plasma, it was not possible 
to determine whether the observed mutations gave the mu-
tant virus a biologically relevant selective advantage. As   eff  orts 
Figure 1.  Sequences of HLA-B*57–restricted Gag epitopes and 
other CTL epitopes in gag genes amplifi  ed from proviral DNA and 
plasma of ES. Areas shaded in blue are optimal HLA-B*57–restricted 
epitopes. Areas shaded in yellow are non–HLA-B*57–restricted epi-
topes that stimulate CD8+ T cell IFN-γ responses in that individual. 
Intervening gag sequence between these epitopes is not shown. The 
first sequence of each group is the gag clade B consensus sequence. 
Homology to this sequence is indicated by a dot. Stop codons are 
indicated by an asterisk (*) in place of an amino acid. Asterisks in 
the “Source” column indicate sequences from resting CD4+ T cells 
with characteristic APOBEC3G-mediated G→A hypermutation. 
Sequences are listed in the following order: hypermutated proviral 
sequences, nonhypermutated proviral sequences, and sequence 
from plasma virus.JEM VOL. 203, May 15, 2006  1359
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to develop an eff  ective vaccine against HIV-1 continue, it is 
extremely important to understand the extent and nature of 
CD8+ T cell escape that is tolerated in ES without loss of 
  viral suppression.
We have studied CTL escape in seven ES who have had 
documented HIV-1 infection for an average of 11 yr. All 
have maintained viral loads of <50 copies/ml of plasma upon 
repeated measurements, and none have received antiretrovi-
ral therapy. We used a novel approach to determine whether 
ongoing selective pressure by CTLs is important for the con-
trol of viremia in ES. Although ES maintain clinically unde-
tectable viral loads, we show here that free virus can be 
detected in the plasma of most of these individuals using sen-
sitive RT-PCR assays. We amplifi   ed near full-length gag 
genes from this plasma virus and from proviral DNA in rest-
ing CD4+ T cells, allowing sequence comparisons between 
the two viral populations. We then tested IFN-γ responses in 
each subject against all well-defi  ned HLA-B*57–restricted 
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epitopes in the HIV-1 genome as well as overlapping pep-
tides spanning the entire gag gene. Finally, we measured rela-
tive IFN-γ production and relative IL-2 responses to 
wild-type Gag epitopes and potential plasma virus escape var-
iants to determine how these responses related to the strong 
selective pressure observed in vivo.
RESULTS
All plasma viruses have mutations in HLA*B57-restricted 
Gag epitopes
Proviral gag and nef sequences were successfully PCR ampli-
fi  ed from resting CD4+ T cells of seven out of seven HLA-
B*57+ ES who had viral loads of <50 copies/ml (Fig. 1). In 
fi  ve out of seven of these subjects, gag sequences were also suc-
cessfully amplifi  ed from free virions in the plasma by an ex-
tremely sensitive RT-PCR method, even though the viral 
load was consistently below the limit of detection of ultrasensi-
tive clinical assays (50 copies/ml). In each of these fi  ve sub-
jects, plasma virus sequences were successfully amplifi  ed on at 
least two diff  erent time points 8–10 mo apart. These results 
provide the fi  rst direct evidence that many ES with viral loads 
of <50 copies/ml experience a chronic state of extremely low 
level viremia. The number of independent gag sequences that 
could be amplifi  ed, particularly in ES3, was limited by the ex-
tremely low viral loads in these subjects. To eliminate the 
problem of PCR resampling (28), only genes amplifi  ed in in-
dependent PCR reactions were considered to be independent. 
Although defective nef genes have been demonstrated in some 
LTNPs (29–31), none of these subjects had any evidence of 
truncations or deletions of proviral nef genes (not depicted).
In all cases where plasma virus could be successfully ampli-
fi  ed, there was a striking discordance between gag sequences 
obtained from this plasma virus and sequences obtained from 
archived provirus in resting T cells. This diff  erence, which was 
observed at all time points, suggests strong selective pressure 
acting on the plasma virus (Fig. 1). Many of the diff  erences 
between cellular proviral gag and plasma virus gag sequences 
occurred in well-defi  ned  HLA-B*57–restricted Gag epi-
topes, including ISPRTLNAW (IW9), K  A  F  S  P  E  V  I  P  M  F 
(KF11), and T  S  T  L  Q  E  Q  I  G  W   (TW10) (32). In the fi  ve 
individuals from whom both cellular provirus and plasma 
virus gag sequences could be amplifi  ed, the mean number 
of amino acid diff   erences between provirus and plasma 
  virus Gag ranged from 6.7 to 8.7 (Table I). A median of 
Table I.  Frequency of mutations in HLA-B*57–restricted epitopes
Study
subject
Mean no.
of A.A. differencesa
between provirus and 
plasma virus Gag
Mean no. of provirus → 
plasma virus A.A. 
changes away
from consensusb
Mean no. of provirus → 
plasma virus
A.A. changes
toward consensusb
Predicted no. of 
A.A. differences at 
A146, I147, T242,
and G248 of Gagc,d
Observed no. of 
A.A. differences at 
A146, I147, T242,
and G248d
ES8 7.5 7.5 0 0.07 2
ES2 8.7 6.4 2.3 0.08 1
ES3 8 7 1 0.07 3
ES7 5.4 2.4 3 0.05 1.3
ES9e 6.7 4.9 1.8 0.06 0
median 7.5 6.4 1.8 0.07 1.3
Study
subject
Fold increase p-value Predicted no. of 
differences in HLA-
B*57–restricted 
epitopesc
Observed no. of 
A.A. differences in 
HLA-B*57–restricted 
epitopes
Fold
increase
p-value
ES8 28.6 <0.001 0.7 4 5.7 <0.001
ES2 12.5 <0.001 0.8 1.4 1.8 NS
ES3 42.9 <0.001 0.7 3 4.3 <0.01
ES7 26 <0.001 0.5 2 4 <0.025
ES9e 0 NS 0.6 0 0 NS
median 26 — 0.7 2 4 —
aMean number of amino acid differences between Gag from provirus and Gag from plasma virus was calculated to include mutations that were present in <100% of the 
proviral Gag quasispecies or <100% of the plasma virus Gag quasispecies. Mutations were only counted in this analysis if they were detected in at least two independent gag 
genes, and hypermutated Gag sequences were not included in the analysis.
bProvirus→plasma virus Gag changes were separated into those where plasma virus diverged more than provirus from the subtype B consensus Gag sequence (“away from 
consensus”) and those where changes in plasma virus Gag were reversions back to the consensus sequence (“toward consensus”).
cPredicted number of amino acid differences at A146, I147, T242, and G248 of Gag or in HLA-B*57–restricted epitopes in Gag was calculated based upon the overall number 
of differences between provirus and plasma virus Gag and assuming a random distribution of mutations across the gene.
dMutations at A146, I147, T242, and G248 were specifi  cally examined because these residues fall within or immediately adjacent to HLA-B*57–restricted epitopes, and 
mutations at these specifi  c amino acids are more frequent in viremic HLA-B*57+ individuals than in viremic HLA-B*57− individuals. Mutations at A146 and T242 have been 
shown to act as CTL escape mutations.
eAll Gag from both provirus and plasma virus in this individual had A146P, I147L, T242N, and G248A mutations. Thus, despite the presence of mutations, there was no change 
in plasma virus relative to provirus at these residues. However, there were an average of 1.5 changes at the HLA-B*27–restricted KK10 epitope in plasma virus Gag relative to 
provirus Gag, which is ninefold greater than the predicted number of changes at this epitope based upon the overall frequency of changes in Gag (P < 0.001).JEM VOL. 203, May 15, 2006  1361
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2 (range: 0–4) of these amino acid diff  erences was within or 
immediately fl  anking HLA-B*57–restricted epitopes. A me-
dian of 1.3 (range: 0–3) of these diff  erences was at A146, 
I147, T242, and G248 of Gag. These amino acids are within 
or immediately fl  anking HLA-B*57–restricted epitopes, and 
they have been shown to mutate more frequently in viremic 
HLA-B*57+ individuals than in viremic individuals who are 
HLA-B*57− (33, 34). In ES8, ES2, ES3, and ES7, the num-
ber of changes at A146, I147, T242, and G248 was 12.5–42.9 
times higher than would be expected if the amino acid diff  er-
ences between provirus and plasma virus Gag in these indi-
viduals were randomly distributed (P < 0.001). The absence 
of amino acid diff  erences between provirus and plasma virus 
Gag in HLA-B*57–restricted epitopes in ES9 could be ex-
plained by the fact that this individual had A146P, I147L, 
T242N, and G248A mutations in all provirus and all plasma 
virus Gag sequences (Fig. 1). All viral clones obtained from 
the plasma showed at least one mutation in an HLA-B*57–
restricted Gag epitope, and some of these changes were mu-
tations previously described in HIV-1–infected HLA-B*57+ 
patients with progressive disease, including I147L in the 
IW9 epitope as well as T242N and G248A in the TW10 
epitope (33, 34). A146P, seen in plasma virus of both ES9 
and ES7, is a processing mutation that blocks presentation 
of the IW9 epitope and causes escape from T cell responses 
to that epitope (33). Plasma viruses of ES9, ES3, and ES7 
bear the T242N mutation in the TW10 epitope. This muta-
tion has been extensively studied in HIV-1–infected patients 
with progressive disease and is known to cause escape from 
CD8+ T cell IFN-γ responses (34, 35). A G248E mutation 
in the TW10 epitope appeared along with I147L in IW9 in 
2 out of 10 nonhypermutated proviral clones of ES6, a subject 
from whom no plasma virus gag could be amplifi  ed. Some 
previously uncharacterized mutations were also observed 
in plasma viruses. These included I147M in the IW9 epitope in
ES8 and ES3, the Q244T/I247V/G248A triple mutation 
in the TW10 epitope of ES8, and E245D in the TW10 epi-
tope of some plasma clones of ES2.
Despite the presence of mutations in all plasma viral gag 
clones, most proviral cellular sequences were entirely wild-
type at HLA-B*57–restricted epitopes, suggesting that these 
subjects were not initially infected with virus bearing HLA-
B*57 escape mutations (Fig. 1). One subject, ES7, showed a 
mixture of wild-type and mutant clones in cellular provirus, 
but 23 out of 23 plasma clones bore HLA-B*57–restricted 
epitope mutations. Collectively, these data suggest that mu-
tations in HLA-B*57–restricted epitopes in this population 
occurred sometime after infection and that these mutations 
likely continue to confer a selective advantage to plasma 
  virus. Another subject, ES9, showed changes relative to sub-
type B consensus in multiple HLA-B*57–restricted epitopes 
in both the cellular provirus and plasma virus. It is therefore 
possible that this subject was initially infected with virus bear-
ing escape mutations in HLA-B*57–restricted epitopes. This 
subject, who is HLA-B*27+ as well as HLA-B*57+, none-
theless showed discordance between cellular and plasma 
  virus, with a L268M mutation at the HLA-B*27–restricted 
Gag epitope K  R  W  I  I  L  G  L  N  K   (KK10) present in all (10 out of 
10) plasma sequences and no (0 out of 27) cellular sequences. 
This mutation has been described previously as a precursor 
mutation required for the development of a R264K escape 
mutation in the same epitope (20, 36).
Substantial numbers of proviral clones from each subject 
showed characteristic APOBEC3G-mediated G to A hyper-
mutation (Fig. 1; references 37–41). Hypermutation of pro-
viral DNA has been observed previously in patients on 
suppressive highly active antiretroviral therapy and in chroni-
cally infected patients (42, 43). Consistent with previous ob-
servations in patients on highly active antiretroviral therapy, 
hypermutated sequences were not detected in the plasma 
(42). The fraction of hypermutated proviral clones varied be-
tween subjects, ranging from 2 out of 13 independent clones 
in ES8 to 13 out of 15 in ES3. The majority of the hyper-
mutated proviral sequences did not carry the HLA-B*57–
  restricted epitope mutations found in plasma virus, which 
is consistent with the hypothesis that these are ancestral, ar-
chived viruses. The signifi  cance of this fi  nding remains un-
clear, as similarly detailed studies involving limiting dilution 
PCR of proviral gag have not yet been performed in other 
HIV-infected populations. It is noteworthy that subjects with 
the highest proportion of hypermutated provirus nevertheless 
had detectable nonhypermutated plasma virus.
CD8+ T cell IFN-𝗄 responses focus on HLA-B*57–restricted 
Gag epitopes
Using ELISPOT assays for IFN-γ production, we assessed 
CD8+ T cell IFN-γ responses to peptides representing the 
wild-type sequences of all well-characterized HLA-B*57–
  restricted epitopes in all HIV-1 genes as well as overlapping 
peptides spanning the entire gag gene (Fig. 2; reference 32). 
Responses were highly focused on HLA-B*57–restricted 
Gag epitopes, as described previously (26, 44), but responses 
to non–HLA-B*57–restricted Gag epitopes were also de-
tected in three patients in at least two independent experi-
ments with CD4+ T cell–depleted PBMCs. ES9, the 
HLA-B*27+ subject, responded to the HLA-B*27–restricted 
K  R  W  I  I  L  G  L  N  K   (KK10) epitope. ES8 responded to a pep-
tide spanning Gag amino acids 17–31 (KK15), which had a 
K26R mutation in a minority of plasma virus clones, and ES7 
responded to three non-B57–restricted peptides spanning 
amino acids 178–192 (EV15), 297–311 (VQ15), and 329–
343 (DL15), none of which showed mutations in plasma 
  virus (Fig. 1). Responses to overlapping peptides containing 
HLA-B*57–restricted Gag epitopes were consistent with 
  responses against optimized HLA-B*57–restricted Gag epi-
topes (not depicted). Although potential escape mutations 
were detected in this population, CD8+ T cells from all sub-
jects except ES9 showed IFN-γ response against at least one 
epitope that was not mutated in either cellular provirus or in 
plasma virus. ES3 showed plasma virus mutations in both tar-
geted Gag epitopes, but an IFN-γ response to the IW9 epi-
tope in the RT gene was also present. We therefore sequenced 1362  CTL ESCAPE IN HLA-B*57+ ELITE SUPPRESSORS | Bailey et al.
the RT gene from plasma virus in this subject and found no 
evidence of mutation in the targeted epitope in clones from 
seven out of seven independent RT-PCR reactions (not 
  depicted). Thus, the presence of epitopes that remain free of 
escape mutations despite targeting by CD8+ T cells may be 
one key for maintenance of suppression in these ES.
Relative CD8+ T cell IFN-𝗄 responses to wild-type and 
mutant epitopes correlate poorly with the persistence 
of plasma virus–bearing mutations in the targeted epitopes
We sought to determine whether the presence of plasma vi-
rus variants with mutations in targeted epitopes correlated 
with relative CD8+ T cell IFN-γ responses to particular epi-
topes. IFN-γ responses by CD8+ T cells from each subject in 
response to plasma virus variants of targeted epitopes were 
analyzed and compared with the response to the correspond-
ing wild-type peptide (Fig. 3). Surprisingly, mutant plasma 
virus epitopes generally stimulated IFN-γ responses that were 
as good as or better than responses to the corresponding wild-
type epitopes. ES8 showed nearly equivalent responses to the 
I147M plasma virus variant and the wild-type proviral form 
of IW9 and a slightly diminished response to the K28R vari-
ant of the non–HLA-B*57–restricted KK15 peptide (Fig. 3, 
A and C). This subject unexpectedly showed a signifi  cantly 
greater IFN-γ response to the Q244T/I247V/G248A plasma 
virus variant of TW10 than to the wild-type proviral epitope 
(Fig. 3 B). In the case of ES2, although I147L was the only 
HLA-B*57–restricted epitope mutation present in all plasma 
viruses, CD8+ T cells from this subject showed equivalent 
IFN-γ responses to the I147L and wild-type form of the IW9 
epitope (Fig. 3 D). This subject had a diminished IFN-γ re-
sponse to the E245D variant of TW10 that was found in some 
plasma viruses (Fig. 3 E). Like ES8, ES3 showed equivalent 
responses to the I147M and wild-type variants of IW9 (Fig. 
3 F). In this subject, there was a strong response to the wild-
type form of the TW10 epitope but no detectable response 
to the T242N/G248A double mutant detected in the plasma 
(Fig. 3 G). This double mutation has been previously shown 
to stimulate a decreased IFN-γ response by CD8+ T cells 
relative to the wild-type TW10 peptide (34). ES9 had nearly 
equivalent responses to the wild-type and mutant versions of 
the KF11 epitope (Fig. 3 H). In addition, response to the 
L268M plasma virus variant of the HLA-B*27–restricted 
KK10 epitope was equivalent to or greater than responses to 
the wild-type and N271H forms found in resting CD4+ T 
cells (Fig. 3 I). ES7 also showed equivalent IFN-γ responses 
to wild-type and I147L plasma virus variants of IW9 (Fig. 3 J). 
As observed in ES3, ES7 responded poorly to the T242N 
variant of TW10 (Fig. 3 K). Although no plasma virus gag se-
quences could be amplifi  ed in ES6, this subject had a minority 
population of cellular virus with the I147L mutation in IW9 
and G248E mutation in TW10. Like the other subjects tested, 
ES6 had equivalent responses to wild-type and I147L forms 
of IW9 (Fig. 3 L). Like ES8, this subject had a signifi  cantly 
greater response to a mutant variant of TW10 (G248E) than 
to the wild-type peptide (Fig. 3 M). Collectively, these re-
sults suggest that although selective pressure apparently leads 
to the appearance of plasma virus variants with mutations in 
CTL epitopes, some of these mutant epitopes stimulate CD8+ 
T cell IFN-γ responses that equal or surpass the responses 
stimulated by wild-type epitopes. The responses of ES8 and 
ES6 to their variant TW10 epitopes are particularly suggestive 
of de novo responses. Overall, relative CD8+ T cell IFN-γ 
responses correlated poorly with persistence of plasma virus 
variants with mutations in the targeted epitopes.
Mutations found in plasma virus gag can potentially 
mediate CTL escape
We asked whether peptides with the mutations found in 
plasma viruses were recognized as well as the corresponding 
Figure 2.  CD8+ T cell IFN-𝗄 responses, expressed as SFCs per mil-
lion PBMCs, to wild-type forms of well-defi  ned HLA-B*57–
  restricted epitopes in all HIV-1 genes and responses to 
non-B57–restricted overlapping peptides spanning the entire gag 
gene. The fi  rst four peptides shown in Gag (IW9, KF11, TW10, and QW9) 
are HLA-B*57 restricted. Epitopes that are mutated in all plasma virus 
gag genes from that individual are indicated by an asterisk (*).JEM VOL. 203, May 15, 2006  1363
ARTICLE
wild-type epitopes by CTLs from other HLA-B*57+ sub-
jects. To examine this possibility, we assessed recognition of 
each mutant plasma virus epitope by epitope-specifi  c T cells 
from other study subjects whose virus did not possess that 
particular mutation (Fig. 4 and Fig. S1, which is available 
at http://www.jem.org/cgi/content/full/jem.20052319/
DC1). The L268M mutation in KK10 could not be tested in 
this manner because no other subjects were HLA-B*27+. All 
mutations aside from I147L and I147M in the IW9 epitope 
were found to result in considerable loss of recognition by 
T cells of multiple subjects. For example, the Q244T/I247V/
G248A triple mutant TW10 epitope that arose in ES8 was 
not recognized by T cells from ES2, ES3, or ES7, although 
T cells from each of these individuals recognized the wild-
type TW10 epitope (Fig. 4 A and Fig. S1). None of these 
  individuals had the Q244T/I247V/G248A triple mutation. 
Figure 3.  IFN-𝗄 responses to autologous mutant epitopes. IFN-γ 
responses by CD8+ T cells from each subject against wild-type targeted 
epitopes and mutant epitopes found in plasma virus or minor proviral 
populations in that individual. ●, responses against wild-type epitopes; 
○, responses to plasma virus mutant epitopes. (A–C) Responses by 
ES8 to wild-type and mutant IW9, TW10, and EH15. (D and E) 
Responses by ES2 to wild-type and mutant IW9 and TW10. (F and G) 
Responses by ES3 to wild-type and mutant IW9 and TW10. 
(H and I) Responses by ES9 to wild-type and mutant KF11 and 
KK10. (J and K) Responses by ES7 to wild-type and mutant IW9 
and TW10. (L and M) Responses by ES6 to wild-type and mutant 
IW9 and TW10.1364  CTL ESCAPE IN HLA-B*57+ ELITE SUPPRESSORS | Bailey et al.
As shown in Fig. 4 B, the G248E mutant TW10 epitope 
detected in ES6 was poorly recognized by T cells from ES7 
and ES3, although T cells from each individual recognized 
wild-type TW10. Interestingly, as shown in Fig. 3, these 
TW10 mutants were strongly recognized by CTLs from ES8 
and ES6, the subject in which the mutation arose. Thus, it 
is appears likely that both patients developed de novo re-
sponses to these variant peptides. The E245D mutant TW10 
epitope detected in ES2 was not recognized by T cells from 
ES8 or ES6, although T cells from each of these individuals 
recognized the wild-type TW10 epitope (Fig. 4 C). T cells 
from ES2, ES5, ES8, ES6, and ES7 recognized the A163S 
variant of the KF11 epitope poorly, although T cells from 
each recognized wild-type KF11 peptide (Fig. 4 D and Fig. 
S1). Collectively, these data suggest that the Q244T/I247V/
G248A triple mutation in the TW10 epitope of ES8, the 
E245D mutation in the TW10 epitope of ES2, the G248E 
mutation in the TW10 epitope of ES6, and the A163S muta-
tion in the KF11 epitope of ES9 can potentially act as CTL 
escape mutations because epitopes with these mutations are 
not recognized by some CTLs specifi  c for other forms of the 
same epitope.
The I147M and I147L mutant variants of the IW9 epi-
tope were recognized as well or nearly as well as the wild-
type form of IW9 by T cells from several subjects. T cells from 
ES7, ES2, ES5, and ES6 showed similar IFN-γ responses to 
wild-type IW9 and the I147M variant (Fig. 4 E and Fig. S1). 
None of these individuals showed evidence of the I147M 
mutation, although virus from ES7, ES2, and ES6 did have 
an I147L mutation in the IW9 epitope. As shown in Fig. 4 F, 
T cells from ES8 and ES3 showed equivalent IFN-γ re-
sponses to the wild-type and I147L forms of IW9, although 
virus in both individuals had an I147M rather than an I147L 
mutation. Collectively, these results suggest that unlike the 
other mutations studied, the I147L and I147M mutations in 
IW9 do not signifi  cantly decrease IFN-γ responses by T cells 
specifi  c for wild-type or other mutant variants of the IW9 
epitope. These mutations may therefore be relatively poor 
mediators of CTL escape or they might aff  ect the processing 
of Gag, preventing the presentation of the optimal epitope. 
This phenomenon has been reported with the I46P mutation 
that immediately precedes this IW9 epitope (33).
Relative CD8+ T cell IL-2 responses to wild-type 
and mutant epitopes correlate with the viral variants 
found in plasma
The relative magnitude of CD8+ T cell IFN-γ responses to 
wild-type proviral epitopes and mutant plasma virus epitopes 
could potentially explain the apparent selective advantage of 
the mutant plasma virus in two subjects, ES3 and ES7. All 
plasma clones in ES3 carried the T242N/G248A mutation 
in the TW10 epitope, which stimulated a signifi  cantly lower 
IFN-γ response than the wild-type epitope in this subject 
(Fig. 3 G). All plasma clones in ES7 carried both the I146P 
Figure 4.  IFN-𝗄 responses to nonautologous mutant epitopes. IFN-γ 
responses against wild-type and mutant epitopes by CD8+ T cells from 
subjects whose virus does not have the mutation being tested. The subject 
providing PBMCs is indicated above each graph. ●, responses against 
wild-type epitopes; ○, responses to mutant epitopes. (A) Responses to 
wild-type TW10 and Q244T/I247V/G248A plasma virus mutant of TW10. 
(B) Responses to TW10 and G248E variant. (C) Responses to TW10 and 
E245A variant. (D) Responses to KF11 and A163S variant. (E) Responses to 
IW9 and I147M variant. (F) Responses to IW9 and I147L variant. Similar 
responses to these epitopes by additional subjects are shown in Fig. S1.JEM VOL. 203, May 15, 2006  1365
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mutation in the IW9 epitope and T242N in the TW10 epi-
tope. I146P has been clearly shown to block presentation of 
the IW9 epitope, which would limit any T cell response to 
that epitope (33). In addition, the T242N variant of TW10 
stimulated a lower IFN-γ response than wild-type TW10 in 
this individual (Fig. 3 K).
The relative magnitude of CD8+ T cell IFN-γ responses 
to wild-type proviral epitopes and mutant plasma virus epi-
topes could not explain the apparent selective advantage of 
the mutant plasma virus relative to proviral wild-type virus in 
the remaining ES. We therefore examined another aspect of 
CD8+ T cell function: the capacity of CD8+ T cells from 
ES to secrete IL-2 in response to wild-type HLA-B*57–
restricted epitopes found in cellular provirus and to mutant 
variants found in plasma virus (Fig. 5). CD8+ IL-2 secretion 
has been shown to be an important correlate of protection 
in mouse models of chronic lymphocytic choriomeningitis 
virus infection (45, 46). In addition, studies have shown that 
the ability of CD8+ T cells to secrete IL-2 in response to HIV 
antigen is lost in HIV-infected patients with progressive dis-
ease but maintained in LTNPs (47–49). As shown in Fig. 5, 
ES8 showed diminished IL-2 secretion in response to the 
Q244T/I247V/G248A plasma virus mutant of TW10 rela-
tive to wild-type TW10, even though IFN-γ response in this 
individual was greater to the mutant epitope than to the 
wild-type epitope. Although plasma virus could not be am-
plifi  ed in ES6, the IL-2 response against wild-type TW10 
and a G248E variant found as a minor proviral population 
was tested. The IL-2 response was greater against wild-type 
TW10 than against the G248E mutant, even though the 
IFN-γ response was greater to the G248E mutant. As with 
the IFN-γ responses, the IL-2 responses were considerably 
greater to the wild-type TW10 epitope than to the mutant 
plasma virus epitopes in ES2, ES3, and ES7. The IL-2 re-
sponses to the plasma variants and wild-type IW9 were es-
sentially equivalent in all of the ES. With the exception of 
some gag clones in ES2, the TW10 and IW9 mutants were 
present on the same viral clones and thus the substantial dif-
ference in the IL-2 response to the TW10 epitopes could ex-
plain the selective advantage of the plasma variants. Overall, 
CD8+ T cell IL-2 responses to mutant plasma virus epitopes 
relative to wild-type epitopes correlated with the selective 
advantage of mutant plasma virus observed in vivo for ES8, 
ES3, ES2, and ES7. Although in vivo selection could not 
be proven in ES6, T cells from this subject also showed 
greater IL-2 secretion against wild-type TW10 than against a 
mutant variant.
DISCUSSION
We have shown that extremely low but detectable levels of 
plasma virus persist chronically in ES with viral loads of <50 
copies/ml of plasma. Comparison of gag gene sequences from 
this plasma virus and sequences from proviruses in resting 
CD4+ T cells provides evidence of strong selective pressure 
favoring viruses with changes in HLA-B*57–restricted epi-
topes in Gag. Despite the low frequency of mutations in pro-
viral cellular gag, mutations in HLA-B*57–restricted epitopes 
were seen in every plasma virus amplifi  ed, suggesting power-
ful ongoing selective pressure targeting these epitopes. This 
study demonstrates that CTL escape mutations arise even in 
HIV-1–infected patients who have the best possible suppres-
sion of viremia. Thus, rather than the absolute presence or 
absence of mutations, the number and nature of mutations 
relative to the breadth of the immune response may be criti-
cal to understanding immune control in ES.
Diff  erent subjects showed varying fractions of proviral 
clones bearing mutations in HLA-B*57–restricted epitopes. 
Archiving of viral quasispecies in resting CD4+ cells is a topic 
under active investigation, especially with regard to drug re-
sistance mutations (50–52). The extremely low frequency of 
proviruses with CTL escape mutations in gag in most ES may 
suggest that the mutant plasma viruses have never replicated 
Figure 5.  IL-2 responses to autologous mutant epitopes. IL-2 
  responses by CD8+ T cells from each subject against wild-type targeted 
epitopes and mutant epitopes found in plasma virus or minor proviral 
populations in that individual. ●, responses against wild type epitopes; 
○, responses to plasma virus mutant epitopes.1366  CTL ESCAPE IN HLA-B*57+ ELITE SUPPRESSORS | Bailey et al.
at high enough levels in these subjects to allow archiving. 
These results also suggest that viruses with escape muta-
tions are not necessarily more likely to evade the immune 
  response and revert to a latent phase of infection in resting 
CD4+ T cells.
Despite CTL escape mutations in plasma virus, the ES 
studied maintained suppression of viremia. This may be at 
least partly due to the fact that all ES aside from ES9 showed 
CD8+ T cell IFN-γ responses against one or more epitopes 
that showed no evidence of mutations in either cellular pro-
virus or plasma virus. This has been observed in chronically 
HIV-infected patients with progressive disease as well, and it 
is not suffi   cient for suppression in those individuals (27, 53). 
It has also been shown, however, that CD8+ T cell responses 
against HIV-1 are generally more functionally impaired in 
patients with progressive disease than in ES (54). A small 
number of fully functional CD8+ T cell responses targeting 
unmutated epitopes in ES may mediate more eff  ective 
control of viremia than a broad array of poorly functional 
  responses in progressors.
In addition to IFN-γ responses against unmutated epi-
topes, CD8+ T cells in some ES showed IFN-γ responses to 
mutant plasma virus epitopes that equaled or surpassed their 
responses to the corresponding wild-type proviral epitopes. 
Although this was not conclusively proven here, the recogni-
tion of escape mutant variants of the TW10 epitope in addi-
tion to the corresponding wild-type epitope by CD8+ T cells 
could be the result of de novo CD8+ T cell responses to es-
cape mutants. Development of de novo responses has re-
cently been described at the TW10 epitope in HIV-1–infected 
infants and at the HLA-A*11–restricted Gag 349–359 epi-
tope in an HIV-1–infected adult (35, 55). It is therefore possi-
ble that the development of de novo responses to escape 
mutants may be an important mechanism for maintaining 
  viral suppression in ES.
CD8+ T cell IFN-γ responses to escape mutant did not 
correlate in all subjects with the apparent selective advantage 
of mutant plasma viruses. This suggests that some IFN-γ 
  responses against wild-type and mutant plasma virus epitopes 
may result from CD8+ T cell responses that are not function-
ally equivalent. We therefore examined another aspect of 
CD8+ T cell function: the capacity of CD8+ T cells from 
ES to secrete IL-2 in response to wild-type HLA-B*57–
  restricted epitopes found in cellular provirus and to mutant 
variants found in plasma virus. The relative IL-2 secretion re-
sponses against the epitopes tested correlated with the selec-
tive advantage of the mutant viruses found in plasma. ES8 
showed very good evidence of selective pressure, with 18 out 
of 18 plasma gag clones bearing HLA-B*57–restricted epi-
tope mutations and 0 out of 13 proviral clones with muta-
tions. Although a better IFN-γ response was seen against the 
mutant TW10 epitope, a stronger IL-2 secretion response 
was seen against the wild-type TW10 epitope found in cellu-
lar provirus. Although plasma virus could not be amplifi  ed 
from ES6, CD8+ T cells from this subject showed a more 
vigorous IL-2 secretion response against the wild-type TW10 
epitope than against the mutant variant found in a minor pro-
viral population. Collectively, these results suggest that in 
some cases, relative CD8+ T cell IL-2 secretion responses 
stimulated by wild-type and corresponding mutant epitopes 
correlate better with selection of the variants found in plasma 
than the relative magnitude of IFN-γ responses.
Subject ES8 is illustrative of the complex interaction be-
tween viral evolution and evolution of CD8+ T cell response. 
Without plasma virus sequencing, we might have concluded 
from IFN-γ results that no CTL escape had occurred in this 
subject. In fact, it is likely that escape did occur, and CD8+ T 
cell responses to escape mutant TW10 epitopes were present 
but functionally inferior to the CD8+ T cell responses to the 
wild-type epitopes. Although the mutations observed here 
have not led to an increase in viremia to clinically detectable 
levels, they may be of critical importance in allowing further 
viral evolution and CTL escape (20, 36). It will be important 
to follow these ES to observe any further changes in viral se-
quence or CD8+ T cell response, which could then be corre-
lated to changes in viral replication and disease progression.
In summary, we have shown that most HLA-B*57+ 
ES with viral loads of <50 copies/ml of plasma maintain a 
chronic state of extremely low level viremia. Mutations in 
HLA-B*57–restricted Gag epitopes were seen in all plasma 
viruses but a minority of cellular proviruses. These escape 
mutants were present in all plasma virus clones, suggesting 
that selection pressure at these epitopes is very strong. The ES 
studied maintained CD8+ T cell IFN-γ responses to both 
wild-type epitopes and many mutant plasma virus epitopes, 
but these responses on their own were generally a poor pre-
dictor of the observed selection pressure. We have not ruled 
out the possibility that the variations seen in the IW9 epitope 
represent processing mutations that aff  ect presentation of the 
optimal epitope. Two patients, ES6 and ES8, appeared to 
develop strong de novo IFN-γ responses to the escape vari-
ants of the TW10 epitope. In these two subjects, CD8+ IL-2 
secretion responses showed better correlation with the plasma 
viral variants that were selected in vivo. It thus appears that 
CD8+ T cell responses to some mutant plasma viral epitopes 
were functionally diff  erent from those to wild-type epitopes. 
CTL escape mutations apparently arise as a result of selective 
pressure acting at HLA-B*57–restricted epitopes in ES, but 
suppression of viremia is maintained. This could be due to 
partially functional and de novo responses against mutant epi-
topes and a highly functional CD8+ T cell response to at 
least one epitope that remains free of escape mutations. The 
relationship between CD8+ T cell response and selection of 
escape mutations in ES may provide key insights into the 
mechanisms of eff  ective suppression of HIV-1.
MATERIALS AND METHODS
Subjects. Inclusion criteria were as follows. Subjects had positive HIV-1 
Western blots and consistently had viral loads of <50 copies/ml without an-
tiretroviral therapy. High resolution HLA typing was performed as described 
previously (56), and all patients were determined to be positive for the HLA-
B*57 allele group. The salient clinical features are shown in Table II. This 
protocol was approved by the Institutional Review Board of Johns Hopkins JEM VOL. 203, May 15, 2006  1367
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University. Informed consent was obtained before phlebotomy. Blood anti-
coagulated in citrate dextrose was centrifuged on Ficoll-Hypaque gradients 
to separate PBMCs and plasma. Plasma was centrifuged a second time to 
  remove any remaining PBMCs.
Plasma HIV-1 RNA quantifi  cation. Viral RNA was quantifi  ed using the 
ultrasensitive Roche Amplicor Monitor System Version 1.5 assay (Roche 
Molecular Systems, Inc.), which has a lower limit of quantifi  cation of 
50 copies/ml.
Genomic DNA and RNA isolation. Magnetic bead depletion was per-
formed on PBMCs to enrich for resting CD4+ T cells as described previ-
ously (57). Genomic DNA was purifi  ed from resting CD4+ T cells using the 
Puregene kit (Gentra). 10–20 ml of plasma from each patient was ultracen-
trifuged at 25,200 g for 2 h at 4° to concentrate plasma virions. Viral RNA 
was isolated from pelleted virions using the QIAGEN Viral RNA isolation 
kit (QIAGEN). In brief, supernatant was removed after centrifugation, and 
pelleted virions were resuspended in the supplied lysis buff  er. RNA was iso-
lated according to the recommended protocol.
PCR and RT-PCR amplifi  cation of gag and nef. To prevent resam-
pling, gag and nef genes were amplifi  ed from provirus in genomic DNA by 
limiting dilution “digital” nested PCR (28). Gag was amplifi  ed using primers 
described previously (27). Nef was also amplifi  ed using primers described 
previously (58). Nested PCR for ES8 was performed with 5′ inner primer 
AGCGGGGGAGAATTAGAT (HXB2 814–831) to include the Gag KK15 
epitope in the amplicon. PCRs were performed at a concentration of DNA 
that would produce less than one out of three positive PCR reactions to 
  ensure clonality. PCR products were gel purifi  ed using the QIAquick Gel 
Extraction kit (QIAGEN) and directly sequenced using an ABI PRISM 
3700 DNA analyzer (Applied Biosystems). Chromatograms were manually 
examined for the presence of double peaks indicative of two templates per 
sequencing reaction. Such sequences were discarded. The RT gene was am-
plifi  ed from viral RNA as described previously (52). Gag was amplifi  ed from 
viral RNA by a one-step RT-PCR protocol with SSII (Invitrogen) with the 
primers described (27). Nested PCR was then performed using the same 
primers used for genomic DNA. Negative control reactions without RT run 
with each RNA sample were invariably negative. RT-PCR products were 
TOPO TA cloned (Invitrogen) before sequencing. To avoid resampling, 
only products of independent PCR reactions were considered to be inde-
pendent viral clones in subsequent analysis. Sequences were assembled using 
CodonCode Aligner, version 1.3.1, aligned using ClustalX, and the align-
ments were manually adjusted in Bioedit. Sequences were translated in 
Bioedit, and the mean number of amino acid diff  erences between all provi-
rus Gag and all plasma virus Gag sequences from each patient was calculated. 
The predicted number of amino acid diff  erences at HLA-B*57–restricted 
epitopes in Gag as well as at A146, I147, T242, and G248 was calculated us-
ing the total number of diff  erences between provirus and plasma virus Gag 
for each patient and assuming a random distribution of mutations. These 
values were then compared with the actual number of mutations observed at 
these amino acids. The signifi  cance of diff  erences between the predicted and 
observed number of mutations at these sites was calculated using the chi-
square test. Sequences have been submitted to GenBank, accession numbers 
DQ315156–DQ315359.
ELISPOT analysis. The IFN-γ ELISPOT assay was performed as de-
scribed previously (59). In brief, 96-well plates that had been precoated with 
monoclonal antibody to IFN-γ were purchased from Mabtech. 105 cells/
well were stimulated with diff  erent concentrations of peptides for 16–18 h. 
The plates were washed with PBS/ 0.1% Tween 20 (Sigma-Aldrich) before 
incubation with a biotinylated anti–IFN-γ monoclonal antibody (7-B6-1; 
Mabtech) for 3 h at room temperature. After washes with PBS/ 0.1% Tween 
20, a 1-h incubation with avidin–peroxidase complex was performed (APC; 
Vector Laboratories). The NovaRed peroxidase substrate (Vector Labora-
tories) was then used to detect IFN-γ–producing cells. The IL-2 ELISPOT 
was performed with a kit (Mabtech) as per the manufacturer’s instruction. 
2 × 105 cells/well were used. All plates were evaluated with an automated 
ELISPOT reader system (Carl Zeiss MicroImaging, Inc.) with KS4.8 soft-
ware by an independent scientist in a blinded fashion (Zellnet Consulting). 
Screening with the IFN-γ ELISPOT assay was performed with pools of fi  ve 
overlapping 15-mer Gag peptides (AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH), and confi  rmatory assays with 
CD4+ T cell–depleted PBMCs were performed. Responses were also tested 
against the following HLA B*57–restricted optimal epitopes: ISPRTLNAW 
(IW9), K A  F  S  P  E  V  I  P  M  F   (KF11), T S  T  L  Q  E  Q  I  G  W   (TW10), QASQEVKNW 
(QW9), IVLPEKDSW (IW9), K  I  T  T  E  S  I  V  I  W   (KW10), KTAVQMAVF 
(KF9), STTVKAACW (SW9), AVRHFPRIW (AW9), ISKKAKGWF 
(IF9), K  A  V  R  L  I  K  F  L  Y   (KY10), H  T  Q  G  Y  F  P  D  W  Q   (HQ10), YFPDWQ-
NYT (YT9), and G  P  G  I  R  Y  P  L  T  F  G  W  C  F   (GF14) (32). These peptides were 
synthesized by the peptide facility at the Johns Hopkins School of Medicine 
Oncology Center. Samples were run in triplicate. Negative controls rou-
tinely had 0–1 spot-forming cells (SFCs)/105 PBMCs for the IFN-γ 
ELISPOT assay and 0–3 SFCs/2 ×105 PBMCs for the IL-2 ELISPOT assay. 
A positive response was defi  ned as a mean value that was >3 SFC/105 
PBMCs. One patient (ES7) had consistently high levels of SFCs in his nega-
tive control well in four separate experiments. For this patient, a positive re-
sponse was defi  ned as a mean value that was fi  ve times greater than the 
negative control.
Online supplemental material. IFN-γ responses to nonautologous mu-
tant epitopes by subjects not shown in Fig. 4 is shown in Fig. S1, which is 
available at http://www.jem.org/cgi/content/full/jem.20052319/DC1.
Table II.  Patient characteristics
Subject Race/Gender/Age First positive 
HIV test
CD4 counta
(cells/μl)
Plasma
HIV-1 RNAb
(copies/mL)
HLA-A HLA-B
ES2 AA/F/50 1986 383 <50 02, 31 570301, 510101
ES3 AA/F/53 1991 677 <50 25, 68 5702, 510101
ES5 AA/F/54 1990 704 <50 23, 68 570301, 5802
ES6 AA/F/49 1992 773 <50 23 570301, 1503
ES7 AA/M/51 1994 1125 <50 30, 32 570301, 8101/8102
ES8 AA/M/53 2003 458 <50 02, 03 570301, 
440201/4419N
ES9 AA/F/55 1999 800 <50 02, 30 570301, 2703
aAt study entry.
bAt all study time points.1368  CTL ESCAPE IN HLA-B*57+ ELITE SUPPRESSORS | Bailey et al.
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